

RADIATION ONCOLOGY RESIDENCY PROGRAM

Competency Evaluation of Resident

Resident's Name:		
Rotation:	Clinical Rotation 6	
Inclusive dates of rotation:		
Director or Associate Director:		
Competency Assessment Scheme:		
<ol style="list-style-type: none"> 1. Unsatisfactory <ul style="list-style-type: none"> • Performance/Knowledge is below standard 2. Needs Improvement <ul style="list-style-type: none"> • Performance/Knowledge is below standards in certain areas and improvement is needed 3. Meets Expectations <ul style="list-style-type: none"> • Performance/knowledge that consistently meets high standards of competency 4. Above Expectations <ul style="list-style-type: none"> • Performance/Knowledge exceeds expectations • Performance/Knowledge is consistently high quality 5. Outstanding <ul style="list-style-type: none"> • Performance/Knowledge is exceptional and consistently superior 		
Evaluation criteria	Competency (from 1 – 5)	Explanatory Notes & Mentor Signature
Brachytherapy – General Aspects		
a. The Resident will be familiar with procedures, hardware, and isotopes used for the treatment of the most common anatomic sites treated with sealed-source radionuclide therapy		
b. The physical characteristics, assay, handling, licensing, and disposal (if applicable) of brachytherapy sources will be learned by the Resident		
c. The Resident must be able to quality assure the computer system used to generate information utilized to plan and treat patients with radionuclide sources		
d. The Resident should be able to show competence in physics and dosimetric services in support of the clinical use of sealed radionuclide sources in the treatment of the following. If a case does not occur or is now extremely uncommon, the Resident should		

<p>perform a mock treatment; or the requirement may be waived at the discretion of the Rotation Supervisor:</p> <ul style="list-style-type: none"> • Biliary duct: intraluminal • Eye plaque • Permanent lung implants: planar • Permanent prostate seed implants: volume interstitial 		
<p>e. The Resident should be able to show competence in physics and dosimetric services in support of the HDR clinical treatments of the following. If a case does not occur or is now extremely uncommon, then the Resident should perform a mock treatment; or the requirement may be waived at the discretion of the Rotation Supervisor:</p> <ul style="list-style-type: none"> • Vaginal cylinder HDR. • Tandem and Ring – Fletcher Suit – HDR. • Interstitial HDR. • Planar intraoperative HDR (IOHDR) 		
<p>f. The Resident should observe and actively participate in as many brachytherapy cases as reasonably possible such that they gain sufficient experience and confidence to do the case themselves. Because some cases do not occur very often, the Resident is expected to place a higher priority on the attendance of brachytherapy cases</p>		
<p>g. The Resident should be able to perform all aspects of the LDR and HDR QA independently (although the Resident will not be asked to do so if it is not within regulations). The Resident should participate in a minimum of two source exchanges</p>		
<p>h. The Resident will be familiar with federal, state, and local regulatory documents related to sealed-source therapy</p>		
<p>i. The Resident will learn and generate two mock treatment plans for an LDR and HDR case</p>		
<p>Brachytherapy - 1: Sealed Radionuclides Sources</p>		
<p>a. Demonstrates an understanding of how commonly used sources are generated</p>		
<p>b. Describes the decay, decay energies (mean energy), and half-lives of commonly used sources</p>		
<p>c. Describes the form and construction of sealed sources</p>		

d. Describes and defines the different units of source strength that have been used in the past and the present		
e. Performs an example decay calculation of the total dose delivered for temporary and permanent implants		
f. Describes personal protection techniques (involving time, distance, and shielding) and safe handling of sealed sources		
g. Describes the appropriate methods of storing radioactive material (with regard to security and accountability)		
h. Performs routine receipt procedures and both checks into inventory and checks out temporary and permanent sources		
i. Performs a source room survey and a quarterly inventory		
j. Describes and, if possible, performs leak checks on sealed sources		
k. Demonstrates an understanding and gains hands-on experience of radioactive material packaging and transportation requirements, e.g., Title 49 of the U.S. Code of Federal Regulations (CFR)		
l. Demonstrates an understanding of the equipment used to calibrate sealed sources		
m. Describes the process by which sealed sources are calibrated		
n. Describes the process by which measurement equipment (e.g., electrometers, well ionization chambers) is calibrated		
o. Explains the theory of operation of a well ionization chamber		
p. Describes and performs an assay for sealed sources		
q. Demonstrates an understanding of licensing issues and requirements (e.g., NUREG 1556)		
r. Describes the operation and appropriateness of different survey instruments (e.g., Geiger–Müller counters, ionization survey meters, scintillation counters)		
s. Demonstrates an understanding of the regulatory requirements pertaining to sealed sources, e.g., state or federal regulations such as Title 10 of the U.S. CFR Part 35 (10CFR35)		

Brachytherapy - 2: Unsealed Radionuclides Sources		
a. Demonstrates an understanding of how commonly used radiopharmaceuticals (e.g., I-131, P-32, Sm-153, Sr-89) are generated		
b. Demonstrates an understanding of the decay, decay energies (mean energy), and half- lives of commonly used radiopharmaceuticals		
c. Describes personal protection techniques (involving time, distance, and shielding) and safe handling of unsealed sources		
d. Describes the process by which unsealed sources are calibrated		
e. Describes the process by which measurement equipment (e.g., dose calibrator) is calibrated		
f. Describes and, if possible, performs an assay for unsealed sources		
g. Demonstrates an understanding of licensing issues and requirements (e.g., NUREG 1556)		
h. Describes the operation and appropriateness of different survey instruments (e.g. Geiger–Müller counters, ionization chambers, scintillation counters)		
i. Demonstrates an understanding of the regulatory requirements for unsealed sources, e.g., state/provincial or federal regulations such as 10 CFR 35		
Brachytherapy - 3: Radiation Protection		
a. Demonstrates an understanding of shielding calculations for primary and secondary barriers (e.g., NCRP 151)		
b. Describes the key parameters necessary to perform a shielding calculation		
c. Describes or performs a shielding calculation for a brachytherapy vault		
d. Describes or performs a radiation survey for a brachytherapy vault		
e. Describes requirements for personal radiation safety badges		
f. Describes labeling, shipping, and receiving requirements for radioactive material		
g. Describes management of an isotope inventory		

h. Describes release criteria for radioactive patients (i.e., patients with temporary or permanent implants and radiopharmaceuticals)		
i. Describes how to handle changes in medical status for radioactive patients (i.e., in cases of medical emergency or death, as per NCRP 155)		
j. Explains the key concepts of state/provincial or federal regulations (e.g., Title 10 of CFR parts 19, 20, and 35)		
k. Demonstrates how to safely operate a remote afterloader unit, including emergency procedures		
Brachytherapy - 4: Clinical Applications		
a. Describes the various brachytherapy sources that have been used clinically in the past and which are used today, as well as the rationale for source selection		
b. Describes how a brachytherapy program is developed		
c. Describes in detail the use and operation of the following different brachytherapy modalities and their advantages and disadvantages: <ol style="list-style-type: none"> 1. Low dose rate (LDR) 2. High dose rate (HDR) 3. Pulsed dose rate (PDR; optional) 4. Electronic (optional) 		
d. Describes and performs verifications of source strength (air kerma rate, S_k) and comparisons between measured and vendor's specifications		
e. Describes radiation protection for radiation workers and visitors		
f. Demonstrates an understanding of commissioning and acceptance of remote after-loaders (RALs)		
g. Demonstrates an understanding of gynecologic (GYN) and genitourinary anatomy		
h. Demonstrates an understanding of the treatment of cervical and endometrial cancers with LDR, HDR, and PDR (optional)		
i. Demonstrates an understanding of prostate cancer and its treatment with HDR and LDR		
j. Treatment planning <ol style="list-style-type: none"> 1. Demonstrates an understanding of treatment planning commissioning 		

<p>2. Performs brachytherapy treatment plans for a cylindrical GYN applicator</p> <p>3. Performs brachytherapy treatment plans for cervical applicator (e.g., tandem and ovoids, tandem and ring)</p> <p>4. Describes the differences between point- and volume-based treatment planning as per the ICRU 38 and the Groupe Européen de Curiethérapie (GEC) European Society for Radiotherapy and Oncology (ESTRO) recommendations</p> <p>5. Develops interstitial brachytherapy treatment plans (e.g., prostate cancer, GYN diseases, sarcoma)</p> <p>6. Develops a brachytherapy treatment plan for an eye plaque (optional)</p> <p>7. Performs an activity/dose calculation for microsphere therapy (optional)</p>		
k. Demonstrates an understanding of applicator acceptance, commissioning, and the performance of periodic QA		
l. Demonstrates an understanding of and participates in/performs periodic spot checks, safety procedures, and source exchange QA, including source calibration		
m. Describes emergency training requirements for RALs (e.g., as specified in 10 CFR 35)		
n. Demonstrates an understanding of quality management programs as required by federal or state/provincial regulations for auditing		
o. Describes the criteria for recording/reporting and the subsequent handling of reportable events		
Brachytherapy - 4: Treatment Planning		
a. Demonstrates an understanding of the source strength of radioactive sources		
b. Describes dose rates and dose calculation formalisms for high-energy brachytherapy dosimetry (HEBD) and low-energy brachytherapy dosimetry (LEBD)		
c. Demonstrates an understanding of the performance of computerized planning of various imaging modalities of LDR and HDR		
d. Describes in detail the advantages and disadvantages of dose optimization		

e. Describes and performs secondary calculations as QA checks for computerized planning		
Brachytherapy - 5: Quality Assurance		
a. Demonstrates an understanding of and performs comprehensive periodic QA (daily, monthly, annually) of a remote afterloader		
b. Describes and performs periodic treatment planning QA		
c. Demonstrates an understanding of implant-specific QA		
Proton Therapy - Basics		
a. Demonstrates an understanding of the theory of operation of proton accelerators currently used in radiation oncology treatment (e.g., synchrotrons and cyclotrons) and their limitations		
b. Demonstrates an understanding of proton percent depth dose in tissue and other media and proton ranges for different energies, e.g., stopping and scattering power and range		
c. Demonstrates an understanding of potential dose deposition uncertainties in proton therapy		
Proton Therapy – Radiobiology		
a. Demonstrates an understanding of the impact of the proton beam quality (e.g., linear energy transfer [LET]) on the relative biological effectiveness (RBE)		
Special Procedures - 2: Stereotactic Body Radiation Therapy (SBRT)		
a. Explains the rationale for SBRT treatments, common treatment sites, and typical dose and fractionation schemes		
b. Describes immobilization and localization systems for SBRT treatments		
c. Describes the use of simulation imaging for SBRT target definition, including multi-modality imaging and 4D imaging for cases requiring motion management		

d. Describes treatment planning objectives for SBRT treatments, including dose limits, dose heterogeneity, dose gradient and fall-off, and beam geometry		
e. Describes treatment verification and delivery for SBRT treatments as well as use of in-room imaging		
f. Addresses the need for motion management in lung and abdomen SBRT treatments		
g. Describes treatment planning system validation tests, and in this context, tissue inhomogeneity corrections and small-field dosimetry measurements		